Tuesday, January 09, 2007 7:30:00 AM PDT | VentureDeal Staff
CA -- Juvaris BioTherapeutics announced that it
has closed its first series A round of $6 million. The company expects to close another $6
million within 120 days, to bring the total series A to $12 million.
The company is developing an immunotherapeutic platform for the treatment of
infectious diseases and cancers using lipid-DNA complexes.
The investment came from the Kleiner Perkins Caufield & Byers Pandemic
& Biodefense Fund, which is a purpose-driven fund that focuses its
investments on treatments or vaccines for pandemics.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
Email Sign Up
© 2016 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.